-
-
-
-
-
-
-
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
atai Life Sciences N.V (ATAI) PT Lowered to $10 at H.C. Wainwright
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Tops Q3 EPS by 45c
-
-
-
-
-
-
-
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Announces Key Clinical Pipeline and Corporate Updates
-
-
-
-
-
-
-
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
-
-
-
-
-
-
-
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
-
1,217,897 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

